FBIO logo

FBIO
Fortress Biotech Inc

9,033
Mkt Cap
$72.78M
Volume
232,352.00
52W High
$4.53
52W Low
$1.65
PE Ratio
-18.91
FBIO Fundamentals
Price
$2.21
Prev Close
$2.26
Open
$2.21
50D MA
$2.66
Beta
0.94
Avg. Volume
397,911.16
EPS (Annual)
-$0.0674
P/B
1.42
Rev/Employee
$811,051.28
$102.27
Loading...
Loading...
News
all
press releases
Fortress Biotech (NASDAQ:FBIO) Issues Quarterly Earnings Results, Misses Estimates By $0.32 EPS
Fortress Biotech (NASDAQ:FBIO - Get Free Report) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the...
MarketBeat·1mo ago
News Placeholder
More News
News Placeholder
Fortress Biotech (NASDAQ:FBIO) Lowered to Hold Rating by Wall Street Zen
Wall Street Zen cut shares of Fortress Biotech from a "buy" rating to a "hold" rating in a report on Saturday...
MarketBeat·2mo ago
News Placeholder
Fortress Biotech (FBIO) Projected to Post Quarterly Earnings on Monday
Fortress Biotech (NASDAQ:FBIO) will be releasing its Q4 2025 earnings before the market opens on Monday, March 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-30-fortress-biotech-inc-stock...
MarketBeat·2mo ago
News Placeholder
Fortress Biotech (NASDAQ:FBIO) Cut to "Hold" at Zacks Research
Zacks Research downgraded Fortress Biotech from a "strong-buy" rating to a "hold" rating in a research note on Monday...
MarketBeat·2mo ago
News Placeholder
Fortress Biotech (NASDAQ:FBIO) Shares Pass Above Two Hundred Day Moving Average - What's Next?
Fortress Biotech (NASDAQ:FBIO) Share Price Crosses Above Two Hundred Day Moving Average - What's Next...
MarketBeat·2mo ago
News Placeholder
Fortress Biotech (NASDAQ:FBIO) Stock Passes Above Two Hundred Day Moving Average - Here's Why
Fortress Biotech (NASDAQ:FBIO) Stock Passes Above 200 Day Moving Average - Should You Sell...
MarketBeat·2mo ago
News Placeholder
FBIO Shares Rally After Unit Sells Priority Review Voucher For $205 Million: Retail Now Pins Hopes On Gene Therapy
Fortress said that its majority-owned unit Cyprium Therapeutics has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher to Sentynl Therapeutics.
Stocktwits·3mo ago
News Placeholder
Fortress Biotech's (FBIO) Buy Rating Reiterated at HC Wainwright
HC Wainwright reiterated a "buy" rating and issued a $17.00 price objective on shares of Fortress Biotech in a research report on Monday...
MarketBeat·3mo ago
News Placeholder
Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average - Here's What Happened
Fortress Biotech (NASDAQ:FBIO) Stock Price Crosses Above 200-Day Moving Average - Time to Sell...
MarketBeat·3mo ago
News Placeholder
Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average - What's Next?
Fortress Biotech (NASDAQ:FBIO) Share Price Passes Above 200-Day Moving Average - Here's Why...
MarketBeat·3mo ago
<
1
2
...
>

Latest FBIO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.